Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Background Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell
death 1 receptor. The combination of chemotherapy and immunotherapy may have …

Background Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like
ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with …

Background Adjuvant therapy with durvalumab, with or without tremelimumab, may have
efficacy in patients with limited-stage small-cell lung cancer who do not have disease …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …